Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Intensiteit behandeling endeldarmkanker afgenomen
feb 2024 | Chirurgie, Endoscopie, Maag-darm-leveroncologie, Radiotherapie